ORIC Pharmaceuticals, Inc.
NASDAQ Global SelectTotal Valuation
ORIC Pharmaceuticals, Inc. carries a market capitalization of 1.33B, placing it among publicly traded companies globally.
| Market Cap | 1.33B |
| Enterprise Value | N/A |
Share Statistics
ORIC Pharmaceuticals, Inc. currently has 103.64M shares outstanding.
| Shares Outstanding | 103.64M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 2.94 |
| P/TBV Ratio | 2.94 |
| P/FCF Ratio | -10.12 |
| P/OCF Ratio | -10.07 |
Financial Position
ORIC Pharmaceuticals, Inc. maintains a current ratio of 13.19, meaning it holds 13.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 13.19 |
| Quick Ratio | 12.76 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -39.80 |
| Return on Assets (ROA) | -37.35 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
ORIC Pharmaceuticals, Inc.'s stock has gained approximately 18.19853% over the past 52 weeks. The 50-day moving average sits at 12.11, while the 200-day moving average is 10.66.
| Beta (5Y) | N/A |
| 52-Week Price Change | 18.19853% |
| 50-Day Moving Average | 12.11 |
| 200-Day Moving Average | 10.66 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -154.99M, while operating income came in at -156.14M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -156.14M |
| Pretax Income | -140.35M |
| Net Income | -140.35M |
| EBITDA | -154.99M |
| EBIT | -156.14M |
| Earnings Per Share (EPS) | -1.35 |
Balance Sheet
Total book value stands at 381.26M, with working capital of 252.94M providing operational flexibility.
| Cash & Cash Equivalents | 264.76M |
| Total Debt | N/A |
| Net Debt | -37.48M |
| Equity (Book Value) | 381.26M |
| Book Value Per Share | 3.68 |
| Working Capital | 252.94M |
Cash Flow
ORIC Pharmaceuticals, Inc. produced -111.64M in operating cash flow over the past twelve months. After subtracting -620,000.00 in capital expenditures, free cash flow totaled -112.26M - equivalent to -1.08 per share.
| Operating Cash Flow | -111.64M |
| Capital Expenditures | -620,000.00 |
| Free Cash Flow | -112.26M |
| FCF Per Share | -1.08 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -15.41 |
| FCF Yield | -9.88 |
Scores
ORIC Pharmaceuticals, Inc. posts an Altman Z-Score of 25.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 25.56 |